# EDGAR Filing Document

**Accession Number:** 0002104204
**File Stem:** 0001193125-26-173780
**Filing Date:** 2026-4
**Character Count:** 23530
**Document Hash:** a6d97fd555e61b619a15c09ae5fea5d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-173780.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001193125-26-173780

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alamar Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0002104204
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364899036
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95626
- **FILM NUMBER:** 26888995

**BUSINESS ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510-626-9888

**MAIL ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Illumina Innovation Fund II, L.P.
- **CENTRAL INDEX KEY:** 0001779218

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
- **BUSINESS PHONE:** (650) 781-9770

**MAIL ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_1.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Alamar Biosciences, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Nicholas Naclerio**<br>500 Lincoln Centre Drive<br>Suite 110<br>Foster City CA 94404<br>650-781-9770

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/20/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Illumina Innovation Fund II GP, L.L.C.** | Name of reporting person<br>**Illumina Innovation Fund II GP, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5856536.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5856536.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5856536.00** | Aggregate amount beneficially owned by each reporting person<br>**5856536.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.8%** | Percent of class represented by amount in Row (11)<br>**8.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** All such shares are held of record by IIF II (as defined in Item 2(a) below). IIF II GP (as defined in Item 2(a) below) is the general partner of IIF II and may be deemed to have voting, investment and dispositive power with respect to these securities. Nicholase Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to share voting, investment and dispositive power with respect to these securities.

The percentage in Row 13 is based on 66,521,425 shares of Common Stock (as defined in Item 1 below) outstanding after the Issuer's initial public offering (excluding the underwriters' option to purchase an additional 1,687,500 shares), as reported in the Issuer's prospectus on Form 424(b)(4) and filed with the Securities and Exchange Commission ("Commission") on April 17, 2026 (the "Prospectus").

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Illumina Innovation Fund II, L.P.** | Name of reporting person<br>**Illumina Innovation Fund II, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5856536.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5856536.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5856536.00** | Aggregate amount beneficially owned by each reporting person<br>**5856536.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.8%** | Percent of class represented by amount in Row (11)<br>**8.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** All such shares are held of record by IIF II. IIF II GP is the general partner of IIF II and may be deemed to have voting, investment and dispositive power with respect to these securities. Nicholas Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to share voting, investment and dispositive power with respect to these securities.

The percentage in Row 13 is based on 66,521,425 shares of Common Stock outstanding after the Issuer's initial public offering, as reported in the Prospectus.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Illumina Innovation Fund III GP, L.L.C.** | Name of reporting person<br>**Illumina Innovation Fund III GP, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**507076.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**507076.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**507076.00** | Aggregate amount beneficially owned by each reporting person<br>**507076.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** All such shares are held of record by IIF III (as defined in Item 2(a) below). IIF III GP (as defined in Item 2(a) below) is the general partner of IIF III and may be deemed to have voting, investment and dispositive power with respect to these securities. Nicholase Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to share voting, investment and dispositive power with respect to these securities.

The percentage in Row 13 is based on 66,521,425 shares of Common Stock outstanding after the Issuer's initial public offering, as reported in the Prospectus.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Illumina Innovation Fund III, L.P.** | Name of reporting person<br>**Illumina Innovation Fund III, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**507076.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**507076.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**507076.00** | Aggregate amount beneficially owned by each reporting person<br>**507076.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** All such shares are held of record by IIF III. IIF III GP is the general partner of IIF III and may be deemed to have voting, investment and dispositive power with respect to these securities. Nicholas Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to share voting, investment and dispositive power with respect to these securities.

The percentage in Row 13 is based on 66,521,425 shares of Common Stock outstanding after the Issuer's initial public offering, as reported in the Prospectus.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Nicholas Naclerio** | Name of reporting person<br>**Nicholas Naclerio** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6363612.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6363612.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6363612.00** | Aggregate amount beneficially owned by each reporting person<br>**6363612.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.6%** | Percent of class represented by amount in Row (11)<br>**9.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The shares reported on this cover page consist of (i) 5,856,536 shares of Common Stock held by IIF II and (ii) 507,076 shares of Common Stock held by IIF III. IIF II GP is the general partner of IIF II and may be deemed to have voting, investment and dispositive power with respect to the shares held by IIF II. IIF III GP is the general partner of IIF III and may be deemed to have voting, investment and dispositive power with respect to the shares held by IIF III. Nicholas Naclerio, a member of the Issuer's board of directors, is the sole managing member of each of IIF II GP and IIF III GP and may be deemed to share voting, investment and dispositive power with respect to the shares held by each of IIF II and IIF III, respectively.

The percentage in Row 13 is based on 66,521,425 shares of Common Stock outstanding after the Issuer's initial public offering, as reported in the Prospectus.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Alamar Biosciences, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
47071 Bayside Parkway, Fremont, CA, 94538

This joint statement on Schedule 13D (this "Statement") is filed with respect to the common stock, par value $0.0001 per share ("Common Stock"), of Alamar Biosciences, Inc., a Delaware corporation (the "Issuer"). Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**Item 4. Purpose of Transaction**

The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise.

Nicholas Naclerio is a member of the Issuer's board of directors. In addition, Nicholas Naclerio, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's non-employee director compensation policy, which became effective upon the effective date of the Registration Statement (as defined below).

Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person.

**(b)**
See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person.

**(c)**
Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

In connection with its purchase of shares of the Issuer's Series C Preferred Stock, IIF II and certain of the Issuer's other investors entered into an Amended and Restated Investors' Rights Agreement, dated February 21, 2024, with the Issuer (the "Rights Agreement"). After the closing of the Offering, the stockholders party thereto are entitled to certain registration rights, including the right to demand that that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing. The terms and provisions of the Rights Agreement are described more fully in the Issuer's Registration Statement on Form S-1 (File No. 333-294697) declared effective by the Commission on April 16, 2026 (the "Registration Statement"), and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference.

In connection with the Offering, IIF II and IIF III have entered into a lock-up agreement, pursuant to which IIF II and IIF III have agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuer's securities held by each of IIF II and IIF III for 180 days following the date of the underwriting agreement for the Offering. The terms and provisions of the lock-up agreement is described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 3 to this Statement and is incorporated herein by reference.

Nicholas Naclerio, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's 2026 Equity Incentive Plan (the "Option Plan"), and the Issuer's non-employee director compensation policy (the "Compensation Plan"). The terms and provisions of the Option Plan and the Compensation Plan are described in the Registration Statement and the full text of which is filed as Exhibit 4 to this Statement and is incorporated herein by reference.

The Issuer has entered into an indemnification agreement with each of its directors and executive officers, including Nicholas Naclerio. The indemnification agreement requires the Issuer, among other things, to indemnify Nicholas Naclerio for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by Nicholas Naclerio in any action or proceeding arising out of his services as a director. The terms and provisions of the indemnification agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the Registration Statement, which is filed as Exhibit 5 to this Statement and is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Illumina Innovation Fund II GP, L.L.C.

**Signature:** /s/ Nicholas Naclerio

**Name/Title:** Nicholas Naclerio, Managing Member

**Date:** 04/23/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Illumina Innovation Fund II, L.P.

**Signature:** /s/ Nicholas Naclerio

**Name/Title:** Nicholas Naclerio, Managing Member of Illumina Innovation Fund II GP, L.L.C., the general partner of Illumina Innovation Fund II, L.P.

**Date:** 04/23/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Illumina Innovation Fund III GP, L.L.C.

**Signature:** /s/ Nicholas Naclerio

**Name/Title:** Nicholas Naclerio, Managing Member

**Date:** 04/23/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Illumina Innovation Fund III, L.P.

**Signature:** /s/ Nicholas Naclerio

**Name/Title:** Nicholas Naclerio, Managing Member of Illumina Innovation Fund III GP, L.L.C., the general partner of Illumina Innovation Fund III, L.P.

**Date:** 04/23/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Nicholas Naclerio

**Signature:** /s/ Nicholas Naclerio

**Name/Title:** Nicholas Naclerio

**Date:** 04/23/2026